B+
Bull case
25%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
IMDX
Insight Molecular DiagnosticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A first-mover FDA authorization for a kitted dd-cfDNA transplant assay could shift IMDX from development story to commercial platform, with February financing reducing immediate balance-sheet stress and management highlighting growing transplant-center engagement [#10-K-2026-03-26] [#PR-2026-03-26].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.4.
What can break
Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.
Momentum
12
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $5.80 · Bear $2.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.25
Why
Momentum12 · Δ7d +4.4
Value41 · Δ7d -0.0
Sentiment49 · Δ7d -5.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.4.
Contradictions & invalidation
- • Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.
- • Commercial adoption claims are still early and not yet supported by meaningful product revenue.
- • The company remains essentially pre-revenue in its kitted product strategy, annual losses are still large, and the core upside depends on regulatory and commercialization milestones that are not yet de-risked; any FDA delay or slower uptake could quickly refocus investors on cash burn [#10-K-2026-03-26] [#PR-2026-03-26].
Catalyst clock
2026-06-30
Runway and loss-profile digestion after Q4/FY2025 results and February financing
Lead driver: Sentiment · See AI snapshot
Momentum
12
9% active weight
Current posture
7d trendFlat
Δ7d
+4.4
Δ21d
-42.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
49
62% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
+4.8
Why this grade
Composite grade D. Momentum 11.8 / Value 41.2 / Sentiment 49.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$139.73M
Beta
1.35
Shares Out
32.72M
P/E (TTM) · Derived
-2.6
P/S (TTM)
48.64
P/FCF (TTM) · Derived
-4.72
Rev YoY
-53.9%
EPS YoY
+0.7%
Gross Margin
-93.4%
Op Margin
-2217.9%
Net Debt
-$8.82M
Current Ratio
2.00
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data